Kallyope
PrivateLast Round
Grant
May 10, 2023
Est. Valuation
$1.14B
Total Funding Raised
$487.2M
Momentum Score
25 /100
Company Overview
Kallyope is a biotechnology company focused on discovering and developing effective, user-friendly oral agents by integrating advanced technologies to enhance understanding of gut-brain biology for therapeutic advancements in human health.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kallyope Comps
Public and private peers based on sector, stage, and business model.
Kallyope Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 10, 2023 | ||||
| Series D | Feb 15, 2022 | ||||
| Series C | Mar 25, 2020 | ||||
| Series B | Dec 5, 2018 | ||||
| Series A | Dec 10, 2015 |
Key People
Founding team and executive leadership
Kallyope Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A, Series D |
| StepStone Group | Series C |
| Lux Capital | Series D, Series B, Series C, Series A |
| The Chernin Group | Series A, Series B, Series C, Series D |
| Two Sigma Ventures | Series D, Series B, Series C |
| The Bill & Melinda Gates Foundation Trust | Grant |
| Casdin Capital | Series D, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Presented Phase 2b migraine study results at the AAN Annual Meeting.
- Mar 5, 2026
Phase 2b results for acute migraine treatment elismetrep presented at AAN Annual Meeting.
Kallyope Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kallyope's valuation, stock price, and market status.
